Industry analyst GlobalData has presented research into the growing market for GLP-1 therapies, noting the significance of Roche’s recent acquisition in this ar 12 January 2024
US biopharma Applied Therapeutics has announced the topline results of the ARISE-HF Phase III trial of AT-001 (caficrestat) in patients with diabetic cardiomyo 8 January 2024
Not long after the first home-grown GLP-1 agonist was approved in China, the country’s thriving biotech sector looks set to progress another novel candidate in 4 January 2024
Hoping to capitalize on a tsunami of interest in GLP-1 agonists for weight loss, Structure Therapeutics has now published Phase IIa for its oral candidate, but 19 December 2023
With all eyes on the growing market for obesity therapies, recent results from a trial of Eli Lilly’s newly-approved weight loss drug Zepbound (tirzepatide) may 12 December 2023
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.